Work

Multi-institutional phase 2 study of TLK286 (TELCYTAtm, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer

Year: 2005

Type: article

Study design: Clinical Trial

Source: International Journal of Gynecological Cancer

DOI: 10.1111/j.1525-1438.2005.00114.x

Authors: J.J. KAVANAGH, D.M. GERSHENSON, H. CHOI, L. LEWIS, K. PATEL, G.L. BROWN, A. GARCIA, D.R. SPRIGGS

Institutions: The University of Texas MD Anderson Cancer Center, Telik, Inc. (United States), University of Southern California, Memorial Sloan Kettering Cancer Center

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2040305814

FWCI: 6.66

Cites: 19

Cited by: 52

Related to: 10